ArticleDiscover oncology2025
Identification of therapeutic targets in lung adenocarcinoma using Mendelian randomization and multi-omics.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) remains associated with limited effective pharmacological treatment options. This study aimed to identify potential therapeutic targets for LUAD through the integration and analysis of multi-omics datasets.
methodsA meta-analysis was conducted using two extensive proteomics datasets, the UK Biobank Proteomics Project (UKB-PPP) and the Fenland study, to identify disease-associated targets for LUAD through the Summary-Data-Based Mendelian Randomization method. Sensitivity analysis, including heterogeneity tests for dependent instruments, were conducted to validate the findings. The prognostic relevance of the identified candidate targets was assessed using transcriptomic data. Functional interactions were explored via protein-protein interaction network analysis, while single-cell analyses were employed to determine cell-specific expression patterns and differentiation trajectories. Potential side effects and therapeutic indications of these targets were evaluated using phenome-wide association studies and pharmacological data mining.
resultsFollowing meta-analysis, a primary significant target, intercellular adhesion molecule 5 (ICAM5), along with potential targets FUT8 and KLK13, were identified as therapeutic candidates for LUAD. FUT8 demonstrated a positive association with LUAD risk (OR = 1.02, p = 0.049), while ICAM5 (OR = 0.88, p = 0.002) and KLK13 (OR = 0.85, p = 0.021) exhibited negative associations. ICAM5 was further identified as an independent prognostic factor for patient survival (HR: 0.788, 95% CI: 0.663-0.936, p = 0.007) and revealed significant diagnostic and prognostic utility in LUAD. ICAM5 expression correlated with various immune infiltration patterns, suggesting potential modulation of the tumor immune microenvironment. Single-cell analysis revealed that ICAM5 did not directly impact LUAD cell differentiation, though its downstream target, MUC1, may contribute to differentiation processes, particularly in KRAS-mutated LUAD. Furthermore, phenome-wide association studies did not reveal substantial evidence of adverse phenotypes linked to ICAM5, supporting its safety profile for drug development.
conclusionICAM5 emerges as a promising biological marker with significant prognostic and therapeutic potential in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.